Triple-negative breast cancer (TNBC) is considered one of the highest-risk subtypes of
breast cancer and has dismal prognosis. Local recurrence rate after standard therapy in the …

The development of immunotherapy agents has revolutionized the field of oncology. The
only FDA-approved immunotherapeutic approach in breast cancer consists of immune …

Simple Summary Triple-negative breast cancer (TNBC) is the most aggressive breast cancer
subtype accounting for approximately 10–20% of all cases. Due to a lack of actionable …

Triple-negative breast cancer (TNBC), a subtype of breast cancer, is defined as lacking
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor …

Triple‑negative breast cancer (TNBC) is a highly heterogeneous and aggressive
malignancy. Due to the absence of estrogen receptors and progesterone receptors and the …

Simple Summary For decades, countless efforts have been devoted to developing targeted
drugs to improve the prognosis of triple-negative breast cancer (TNBC). Among the novel …

Triple-negative breast cancer constitutes~ 15% of all breast cancer subtypes. Because of the
negative hormone receptor and human epidermal growth factor receptor 2 status, therapy is …

Triple-negative breast cancer (TNBC) is a highly complex, heterogeneous disease and
historically has limited treatment options. It has a high probability of disease recurrence and …

Background: Triple-negative breast cancer (TNBC) represents an aggressive breast cancer
subtype with historically poor overall outcomes, due primarily to a lack of effective targeted …

Abstract Triple Negative Breast Cancer (TNBC) is a highly heterogeneous subtype of breast
cancer that lacks the expression of oestrogen receptors, progesterone receptors and human …